Stocks Health care QTTB
NASDAQ · Health careQ32 Bio Inc. (QTTB)
In fiscal 2025 capital spending exceeded operating cash flow by $33.5M. At September 30, 2026 it held $289.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Q32 Bio Inc.
- Net worth
- Q32 Bio Inc. has a market value (market cap) of $277.7M at the latest share price, and shareholders' equity of $287.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $53.7M, with net income of $29.8M.
- Cash flow
- In fiscal 2025 operations used $33.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Q32 Bio Inc.'s next report is expected around March 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Q32 Bio Inc. does
Q32 Bio Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker QTTB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $53.7M | $29.8M | $2.42 | -$33.5M |
| 2024 | $0 | -$47.7M | -$6.58 | -$67.8M |
| 2023 | $1.2M | -$53.7M | -$153.96 | -$18.7M |
| 2022 | $3.2M | -$5M | -$7.11 | -$114.9M |
| 2021 | $34M | -$95.8M | -$136.59 | -$112.1M |
| 2020 | $2.7M | -$128.7M | -$221.07 | -$98.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where QTTB ranks in Health care
Latest SEC filings
What Q32 Bio Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026
- November 4, 2026
- October 28, 2026Passive stake (5% or more) SCHEDULE 13G
- October 9, 2026Passive stake (5% or more) SCHEDULE 13G
- September 30, 2026
- September 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Q32 Bio Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $320.4K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 6, 2026 | Kalowski LeeCFO and President | Sold | 1,301 | $10.8K |
| October 6, 2026 | Violette Shelia M.Chief Scientific Officer | Sold | 917 | $7.6K |
| October 6, 2026 | Morrison Jodie PopeCEO, Director | Sold | 3,221 | $26.8K |
| August 25, 2026 | Violette Shelia M.Chief Scientific Officer | Sold | 2,798 | $46.3K |
| August 25, 2026 | Morrison Jodie PopeCEO, Director | Sold | 9,845 | $163K |
| August 25, 2026 | Kalowski LeeCFO and President | Sold | 3,972 | $65.8K |
| July 16, 2026 | Kalowski LeeCFO and President | Received as pay | 53,250 | - |
| July 16, 2026 | Morrison Jodie PopeCEO, Director | Received as pay | 132,000 | - |
Who owns QTTB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Orbimed Advisors LLC13D, may seek influence with 2 related filers | 13.9% | July 20, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | June 4, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.8% | June 4, 2026 |
| Boxer Capital Management, LLC13G, passive with 3 related filers | 7.9% | November 6, 2026 |
| Bank of America Corp13G, passive | 7.4% | October 28, 2026 |
| Acorn Bioventures, L.P.13D, may seek influence with 2 related filers | 6.7% | April 4, 2024 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 8 related filers | 5.9% | October 9, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 71 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Orbimed Advisors LLC | 4,127,987 | +1,875,000 |
| Boxer Capital Management, LLC | 3,149,310 | new |
| Atlas Venture Life Science Advisors, LLC | 2,717,106 | +625,000 |
| Bvf Inc | 2,350,000 | new |
| RA Capital Management, L.P. | 2,332,457 | new |
| Point72 Asset Management, L.P. | 1,173,396 | new |
| Opaleye Management Inc. | 931,000 | -325,228 |
| Logos Global Management LP | 800,000 | new |
| SummitTX Capital, L.P. | 733,774 | new |
| Vanguard Capital Management LLC | 518,803 | +212,402 |
| Ikarian Capital, LLC | 430,000 | new |
| Woodline Partners LP | 286,212 | new |
| American Century Companies Inc | 272,752 | +253,982 |
| Sanofi | 244,083 | 0 |
| Acorn Capital Advisors, LLC | 216,171 | -98,881 |
| Renaissance Technologies LLC | 179,600 | -27,315 |
| Jane Street Group, LLC | 162,747 | +97,148 |
| Monimus Capital Management, LP | 132,036 | -2,274 |
| Boothbay Fund Management, LLC | 130,427 | new |
| Geode Capital Management, LLC | 122,690 | +4,538 |
Insiders
6 insiders reported holding 1,907,583 shares in total, about $17.8M at the last price.
| Holder | Shares |
|---|---|
| Orbimed Advisors LLCDirector, 10% owner | 625,000625,000 held indirectly |
| Xu DiyongDirector, 10% owner | 625,000625,000 held indirectly |
| Morrison Jodie PopeCEO, Director | 340,038 |
| Kalowski LeeCFO and President | 137,170 |
| Violette Shelia M.Chief Scientific Officer | 126,854 |
| Manke IsaacDirector | 53,521 |
Questions about QTTB
What does Q32 Bio Inc. do?
Q32 Bio Inc. is a company in the Health care sector, listed on NASDAQ as QTTB. Its shares trade on NASDAQ under the ticker QTTB.
What is Q32 Bio Inc.'s net worth?
Q32 Bio Inc. has a market value (market cap) of $277.7M at the latest share price, and shareholders' equity of $287.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Q32 Bio Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $32.3M.
When did Q32 Bio Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 6, 2026.
When is Q32 Bio Inc.'s next earnings report?
Q32 Bio Inc.'s next report is expected around March 9, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare QTTB with
Follow QTTB
Get an email when Q32 Bio Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Q32 Bio Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.